ABEO Abeona Therapeutics Inc

$ABEO Ever see a stocks share price double or more in one day? Other than some fantastic news causing that, the usual reason is that a stock was being mispriced by the market for some reason or reasons and then the market came to its senses and decided to fairly value it. This is especially possible whan a stock has a very high short interest like ABEO's which is over 30%. These types of situations can cause huge gains in wealth for those in a position to take advantage. On the other hand it can cause a huge loss of wealth for those participating in the high risk business of shorting a currently mispriced stock.

$ABEO life in Biotech. Bears want to scare you into selling, saying this company is going to zero. I owned IOVA a year ago in the $2-3 range. Bears were also saying to sell it, it is now at $8 and was recently as high as $15. Know what you own. Patience.

$ABEO Another major conference next week, Jefferies Global. So far there has been no major downgrade of Abeona. Has there been any influence here of technical websites that declare low priced stocks to be in technical breakdowns, and then issue target prices which may help to push them even lower? In some of these cases the prices seem to become detached from the reality of the company, and it's just playing with numbers.

$ABEO Looking back @ today it was a very SHADY move from the company to announce earnings with no advanced PR regarding the date .......couple that with the fact that moving forward their NOT announcing biopsy performed....trust in ABEO @ least for me is at a low

$ABEO an inexplicable sequence here for shareholders. Unless they feel ABO-801 is a slam dunk, absolutely no reason to raise money and dilute with the stock near 2 year lows. If you had any confidence in zevaskyn reaching profitability near term, you'd wait to use a more valuable stock as currency. The stock price today reflects zero confidence in management and the board's ability to execute and allocate capital in manner consistent with their fiduciary duty to shareholders. Worrisome is the suspicious timing, which follows Russell's approach to the board, immediately circling the wagons and diluting his stake. Essentially a slap in the face. 1/3

$ABEO Rare updated Fayuvi (UX-111) on their earnings call. Looks like patients will be treated in Q4 and they will be pursuing ex-US approvals. Bullish for $ABEO

$ABEO I’m still holding long at 16k shares at $4.36. I find the easiest thing to do for the next 6 months is block out the noise, mute the people here saying we’re going to zero and enjoy doing other things. I’ll wait for the confirmation that the remaining QTC’s have biopsied and then start averaging down. Management have royally screwed with an awful launch of Zevaskyn and now forcing shareholders to join them on their empire building quest when I’m sure most of us were here for Zevaskyn only plus the benefit of the $RARE and $TSHA payments. Ah well. A much slower ride than the 18 months I was planning to hold the stock, now more likely 3 years.

$ABEO These guys are like: gosh, we’re really having trouble with launching Zevaskyn successfully- let’s invest in an oral me-too that is in a highly competitive market that will be “easier” to impress rather than focusing all of our small biotech attention on fixing what we’re doing wrong with Zevaskyn. Not. Impressed.

$ABEO The current insane share price is probably the result of: 1. A misconception that the ABO-801 purchase and Phase 3 expenses will immediately affect earnings. But the company has stated Phase 3 will not begin at least until mid 2027. 2. ABEO missed revenue estimates. Even though it was only by about 1/2 million, any miss these days gets punished badly and combined with the $30M stock issue, it was greatly over done. 3. But since the price dropped so much at this time of year ABEO became a good candidate for tax loss selling. 4. The 4th quarter is always a slow one for companies like ABEO dealing with surgical procedures. So putting all these together we are where we are. But none of this has anything to do with the expected success of Zevasky or FAYUVI or the company itself or the real share value which over the next few months should be several times what it is now. Great opportunity to initiate a position or add to one.

$ABEO Digging into potential treatment numbers for Q3: As of last earnings report (8/13), they stated 3 treatments thus far, though 1 won't recognize rev due to being out of spec. Assuming the 3 treatments were Stanford, Lurie, and CHOP. They stated at the time, UTMB has biopsied. FB posts have a family sharing their child's journey with Zevaskyn and going in for a biopsy in early September. Confirmed treatment took place (through the posts) at the end of September. This likely means another patient had already been biopsied and likely treated beforehand, so (+2) from UTMB. So if the other centers did not treat for the remainder of the qtr, that is a 5 treatment floor. Considering Stanford and Lurie alone did 5 treatments in Q2, and were likely 2 out of the 3 treatments as of last earnings, at their current cadence, likely +3-4 treatments to match Q2. I think we are highly likely to be at base 8-9 treatments for Q3. 1/2

$ABEO - Daily reminder - to just breathe - let this company do its thing. It is in its first commercial year, its building its centers which is crucial to support possible patients. They already have a secondary revenue stream with $30MIL and royalties moving forward.... Not to mention its a life saving product that no one else has..... Just breathe.... and think 3yrs from now

$ABEO GET YOUR FREE STUFF. ABEO currently has $165M in cash. ABEO currently has 57M shares outstanding. That comes out to cash per share of $2.90. That means that every share bought now at $2.44 is getting a cash bonus of .46 per share and Zevaskyn, ABO-801 and the income and royalties from FAYUVI for FREE.

$ABEO back in with 16k shares at $4.35 (sold out and got back in for a whole $0.05 less than my original position I sold 100% of) useless and goes to show if you’re happy with your position leave it alone!

$ABEO In addition to stuff listed below, there's a big one for Rett syndrome: TSHA-102. From ABEO's 10-K: "(iv) high single-digit royalty-based payments based on net sales". TSHA is going to report 6 month results and possibly file for approval in H1 2027. BoA estimates 2031 peak sales around 2 billion which would mean 100+ million pure yearly profit for ABEO. This is again in addition to everything else they have going. The current share price is ridiculous, but that's how things go when people don't have enough patience and/or knowledge.

$ABEO Based on the list below I think it's clear that however is still selling shares at this price hasn't done his/hers homework and/or is just forced to sell. And other way around however can buy at this price is getting free money handed to him/her, only thing needed is willingness to wait until current craziness passes and current panic sellers get rid of all their shares.

$ABEO they have 136 Million in cash (not counting the 35 million raise) with their current mkt cap of 142 million.......so now trading below their cash on hand.am i missing something????

$ABEO Regretfully, $4.70 avg and over 53,000 shrs holding is a disaster on paper. I'm devastated at the moment.

$ABEO - Continuous good signs... "Abeona Therapeutics 13D Filing Shows James Russell Revocable Trust Raises Stake In Co To 6.1% As Of October 15, 2026" Happy Happy Times....

$ABEO - New centers and new employee RSU's is the thing to remember - they are building a base to launch off of.....

$ABEO Individual Investor Daniel Kaufman has filed a 13G showing a 7.3% holding in Abeona (4.16M shares).